Mixed results with baricitinib in biological-resistant adult-onset Still’s disease and undifferentiated systemic autoinflammatory disease
- Resource Type
- Authors
- Kacar, M; Fitton, J; Gough, AK; Buch, MH; McGonagle, DG; Savic, S
- Source
- RMD open, vol. 6, no. 2, pp. 1-5, 2020.
- Subject
- nediferencirana sistemska avtovnetna bolezen
arthritis
antirheumatic agents
ankylosing spondylitis
adult onset Still's disease -- drug therapy
disease-modifying antirheumatic drugs
ankilozirajoči spondilitis
antirevmatična sredstva
imunomodulirajoči antirevmatiki
undifferentiated systemic autoinflammatory disease
udc:616-002
Stillova bolezen s pričetkom v odrasli dobi -- zdravljenje z zdravili
artritis
- Language
- English
- ISSN
- 2056-5933
This clinical case series describes our experience with the use of Janus kinase 1/2 inhibitor baricitinib in two patients suffering from refractory adult-onset Still’s disease (AOSD) as well as in one case suffering from AOSD-like autoinflammatory disease in the context of myelodysplastic syndrome. All patients suffered from disease non-responsive to conventional Disease-modifying antirheumatic drugs (DMARDs) as well as biological therapies including interleukin (IL)-1 and IL-6 blockade, relying instead on high daily doses of prednisolone. We also report the first case of Pneumocystis jirovecii infection following baricitinib use.